Inspire Medical Systems, Inc. Announces Additional 11.2 Million Covered Lives with New Blue Cross Blue Shield Coverage Policies

Download as PDF

MINNEAPOLIS, MN – May 6, 2019 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a
medical technology company focused on the development and commercialization of innovative and
minimally invasive solutions for patients with obstructive sleep apnea, announced today the addition of
three new Blue Cross Blue Shield Association (“BCBSA”) plans, including Blue Cross Blue Shield of
Michigan, Blue Shield of California and Excellus Blue Cross Blue Shield, adding 11.2 million covered
lives to the growing slate of positive coverage policies of Inspire therapy.

Details of the three new positive coverage policies that all became effective on May 1, 2019, include:
• Blue Cross Blue Shield of Michigan covers approximately 6.1 million members;
• Blue Shield of California covers approximately 3.6 million members; and
• Excellus Blue Cross Blue Shield covers approximately 1.5 million members in New York.

There have now been 21 positive coverage policies issued by BCBSA healthcare plans, covering
approximately 53 million members, following BCBSA Evidence Street’s January 7, 2019 report, which
stated that there is sufficient evidence to determine that Inspire therapy results in a meaningful
improvement in net health outcomes for patients meeting specified criteria. In aggregate, 32 coverage
policies from BCBSA and other healthcare plans representing approximately 83 million members now
cover Inspire therapy.

“The Inspire team continues to work with physicians and payers to develop positive coverage policies,
thereby improving patients’ access to the therapy,” said Tim Herbert, President and Chief Executive
Officer of Inspire Medical Systems. “We have reported on a multitude of new policies to date in 2019,
and remain focused on continuing this momentum with all payers in the United States.”

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s
proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides
a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-
looking statements, including, without limitation, statements regarding future positive insurance coverage.
In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’
‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’
‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these
terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are based on management’s current expectations and involve known
and unknown risks and uncertainties that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the
annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the
U.S.; future results of operations, financial position, research and development costs, capital requirements
and our needs for additional financing; commercial success and market acceptance of our Inspire therapy;
our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system
or any future products we may seek to commercialize; competitive companies and technologies in our
industry; our ability to enhance our Inspire system, expand our indications and develop and
commercialize additional products; our business model and strategic plans for our products, technologies
and business, including our implementation thereof; our ability to accurately forecast customer demand
for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract
manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand,
manage and maintain our direct sales and marketing organization, and to market and sell our Inspire
system in markets outside of the U.S.; risks associated with international operations; our ability to manage
our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our
ability to hire and retain our senior management and other highly qualified personnel; risk of product
liability claims; risks related to information technology and cybersecurity; risk of damage to or
interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire
therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or
other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including
healthcare reform measures in the U.S. and international markets; the timing or likelihood of regulatory
filings and approvals; risks related to our debt and capital structure; our ability to establish and maintain
intellectual property protection for our Inspire therapy and system or avoid claims of infringement; tax
risks; risks that we may be deemed an investment company under the Investment Company Act of 1940;
regulatory risks; the volatility of the trading price of our common stock; and our expectations about
market trends. Other important factors that could cause actual results, performance or achievements to
differ materially from those contemplated in this presentation can be found under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations“
in our Annual Report on Form 10-K filed with the SEC on February 26, 2019, as such factors may be
updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at
www.sec.gov. These and other important factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this presentation. Any such forward-looking
statements represent management’s estimates as of the date of this presentation. While we may elect to
update such forward-looking statements at some point in the future, unless required by applicable law, we
disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should
not assume that our silence over time means that actual events are bearing out as expressed or implied in
such forward-looking statements. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this press release.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989